(firstQuint)A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study.

 This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age or older.

 This study is designed to further characterize the safety profile and gather additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or cellulitis/erysipelas.

.

 A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study@highlight

Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.

